{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:48:40Z","timestamp":1782740920314,"version":"3.54.5"},"reference-count":69,"publisher":"SAABRON PRESS","issue":"2","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative treatment for patients with relapsed or refractory hematologic malignancies, offering new possibilities beyond conventional transplantation. Since their approval in high-income countries, CAR-T products have demonstrated remarkable efficacy; however, their implementation in low- and middle-income countries (LMICs) remains limited due insufficient infrastructure, complex regulatory requirements and high costs. In some countries, like Mexico, these barriers are particularly pronounced, with limited access to clinical-grade vectors, early phase clinical research programs, and lack of government and private sector infrastructure and funding opportunities. Facing these challenges, there is a substantial patient population with B-cell acute lymphoblastic leukemia, multiple myeloma, or diffuse large B-cell lymphoma, who could benefit from CAR-T therapy. Advances in point-of-care manufacturing within academic settings \u2013particularly the use of closed, semi-automated systems\u2013 have demonstrated feasibility in LMICs, by reducing costs and simplifying procedures, while maintaining product quality. These approaches may provide a viable alternative to commercial products, with the potential to lower the economic burden and increase accessibility. Regulatory innovation with the establishment of expert multidisciplinary oversight committees, will also be critical to ensure safe implementation. Ultimately, CAR-T therapy in LMICs is both a scientific and public health opportunity, and its integration into healthcare systems will depend on collaborative strategies that address financial, logistical, and policy barriers. By highlighting our experience, this review underscores the importance of developing locally adapted solutions to expand access to advanced cellular therapies in resource-constrained settings.<\/jats:p>","DOI":"10.46989\/001c.163505","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:15:42Z","timestamp":1782738942000},"source":"Crossref","is-referenced-by-count":0,"title":["Current landscape of academic and point of care CAR-T cell therapy in low-middle income countries"],"prefix":"10.46989","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4732-3013","authenticated-orcid":false,"given":"Sof\u00eda I.","family":"Quezada-Ram\u00edrez","sequence":"first","affiliation":[{"name":"Hematology Service, Hospital Universitario \u201cDr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-6856","authenticated-orcid":false,"given":"Jos\u00e9 E.","family":"Montelongo-Cepeda","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario \u201cDr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2799-3144","authenticated-orcid":false,"given":"Gabriel A.","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario \u201cDr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3213-5810","authenticated-orcid":false,"given":"Rosario","family":"Salazar-Riojas","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario \u201cDr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1264-8133","authenticated-orcid":false,"given":"Dalila M.","family":"Alvarado-Navarro","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario \u201cDr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6904-9345","authenticated-orcid":false,"given":"Andr\u00e9s","family":"G\u00f3mez-De Le\u00f3n","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario \u201cDr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-6427","authenticated-orcid":true,"given":"David","family":"G\u00f3mez-Almaguer","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario \u201cDr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d, Universidad Aut\u00f3noma de Nuevo Le\u00f3n, Monterrey, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/s12967-025-06400-x","article-title":"Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility","volume":"23","author":"D. Gupta","year":"2025","journal-title":"J Transl Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.bglo.2025.100007","article-title":"Latin America and evolving oncotherapeutics using CAR T cells, conjugated antibodies, and bispecific antibodies","volume":"1","author":"R. Sackstein","year":"2025","journal-title":"Blood Glob Hematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1304805","DOI":"10.3389\/fonc.2023.1304805","article-title":"Childhood leukemias in Mexico: towards implementing CAR-T cell therapy programs","volume":"13","author":"J. C. Bustamante-Ogando","year":"2024","journal-title":"Front Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/ejh.14076","article-title":"CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?","volume":"112","author":"A. N. Khan","year":"2024","journal-title":"Eur J Haematol"},{"key":"ref5","article-title":"Global Burden of Disease Study 2021 (GBD 2021)","author":"Global Burden of Disease Collaborative Network","year":"2024"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1002\/cam4.1513","article-title":"Survival analysis of adult patients with ALL in Mexico City: first report from the Acute Leukemia Workgroup","volume":"7","author":"E. Crespo-Solis","year":"2018","journal-title":"Cancer Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"9429","DOI":"10.1182\/blood-2022-171102","article-title":"Treatment Patterns and Survival of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma in Latin America","volume":"140","author":"S. A. V. G. Gossen","year":"2022","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/bjh.16124","article-title":"Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008\u20132016","volume":"188","author":"V. T. De Moraes Hungria","year":"2020","journal-title":"Br J Haematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"M. Crump","year":"2017","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1200\/JCO.1999.17.2.534","article-title":"Autotransplants for Hodgkin's Disease in Patients Never Achieving Remission: A Report From the Autologous Blood and Marrow Transplant Registry","volume":"17","author":"B. H. M. Lazarus","year":"1999","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1182\/blood.2023022922","article-title":"The present and future of CAR T-cell therapy for adult B-cell ALL","volume":"145","author":"A. Rampotas","year":"2025","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1182\/blood-2019-127582","article-title":"Treatment with Novel Agents in Patients with Multiple Myeloma in M\u00e9xico: Data of Characteristics, Treatment Patterns and Outcomes from a Health Care System","volume":"134","author":"F. P\u00e9rez-Jacobo","year":"2019","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMc2403705","article-title":"CAR T-Cell Therapy in Autoimmune Disease","volume":"390","author":"J. F. Howard","year":"2024","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going?","volume":"7","author":"M. Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jtct.2022.07.015","article-title":"Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective","volume":"28","author":"S. R. Goldsmith","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s12032-018-1204-6","article-title":"Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis","volume":"35","author":"K. Nagle","year":"2018","journal-title":"Med Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41408-024-01084-w","article-title":"Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission","volume":"14","author":"M. Shadman","year":"2024","journal-title":"Blood Cancer J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","article-title":"How I treat relapsed childhood acute lymphoblastic leukemia","volume":"120","author":"F. Locatelli","year":"2012","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jcyt.2024.11.016","article-title":"Post-transplant relapse in pediatric acute lymphoblastic leukemia in the era of CAR-T cell therapy. A multicenter analysis of Grupo Espa\u00f1ol de Trasplante Hematopoyetico y Terapia Celular (GETH-TC) Pediatric Committee","volume":"27","author":"M. Gonz\u00e1lez Vicent","year":"2025","journal-title":"Cytotherapy"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"544.e1","DOI":"10.1016\/j.jtct.2024.02.020","article-title":"Improving Unrelated Donor Equity: Assessing Mismatched Donor Opportunities with Real-World Data in a Minority-Predominant Cohort","volume":"30","author":"M. B. Hammami","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41409-023-01949-x","article-title":"Role of allogeneic hematopoietic cell transplant for relapsed\/refractory aggressive B-cell lymphomas in the CART era","volume":"58","author":"A. Mussetti","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12935-025-03938-0","article-title":"Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions","volume":"25","author":"J. Zhu","year":"2025","journal-title":"Cancer Cell Int"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.3390\/cancers12113445","article-title":"Complications after CD19+ CAR T-Cell Therapy","volume":"12","author":"O. Penack","year":"2020","journal-title":"Cancers"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.bbmt.2019.07.028","article-title":"Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis","volume":"25","author":"L. J. Arcuri","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/s41409-021-01321-x","article-title":"The paradox of haematopoietic cell transplant in Latin America","volume":"56","author":"G. Jaimovich","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jtct.2022.02.011","article-title":"Hematopoietic Stem Cell Transplantation in Nepal: International Partnership, Implementation Steps, and Clinical Outcomes","volume":"28","author":"B. S. Poudyal","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e2400581","DOI":"10.1200\/GO-24-00581","article-title":"Decentralized Point-of-Care Manufacturing of CD19 Chimeric Antigen Receptor T Cells in Mexico","author":"R. Salazar-Riojas","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"103138","DOI":"10.1016\/j.eclinm.2025.103138","article-title":"Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial","volume":"81","author":"A. Ghobadi","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"103471","DOI":"10.1016\/j.retram.2024.103471","article-title":"Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed\/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression","volume":"72","author":"I. Danylesko","year":"2024","journal-title":"Curr Res Transl Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/ajh.25274","article-title":"Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia","volume":"93","author":"E. Jacoby","year":"2018","journal-title":"Am J Hematol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.1182\/bloodadvances.2024012982","article-title":"Point-of-care CAR T manufacturing solutions: can 1 model fit all?","volume":"8","author":"\u00c1. Urbano-Ispizua","year":"2024","journal-title":"Blood Adv"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-LBA-1","article-title":"Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti\u2013B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010","volume":"146","author":"S. Harrison","year":"2025","journal-title":"Blood"},{"key":"ref33","article-title":"KYMRIAH","author":"Food and drug administration (FDA)","year":"2025","journal-title":"FDA"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1586912","DOI":"10.3389\/fbioe.2025.1586912","article-title":"Closed-system manufacturing of therapeutic NK cells using automated cell enrichment and concentration processes enables scalable, robust and cost-effective solutions","volume":"13","author":"N. Kok","year":"2025","journal-title":"Front Bioeng Biotechnol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"27483","DOI":"10.17226\/27483","article-title":"Emerging Technologies and Innovation in Manufacturing Regenerative Medicine Therapies: Proceedings of a Workshop-in Brief","author":"Forum on Regenerative Medicine","year":"2024"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/cite.201200175","article-title":"Integrated Clinical Scale Manufacturing System for Cellular Products Derived by Magnetic Cell Separation, Centrifugation and Cell Culture","volume":"85","author":"M. Apel","year":"2013","journal-title":"Chem Ing Tech"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","article-title":"Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy\u00ae: real-world experience and cost analysis in India","volume":"58","author":"H. K. Palani","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.htct.2019.06.007","article-title":"Establishment of a simple and efficient platform for car-t cell generation and expansion: from lentiviral production to in vivo studies","volume":"42","author":"V. Pican\u00e7o-Castro","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/s41409-024-02283-6","article-title":"Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory\/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil","volume":"59","author":"C. D. Donadel","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"200889","DOI":"10.1016\/j.omton.2024.200889","article-title":"Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand","volume":"32","author":"S. Luanpitpong","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/biom15081166","article-title":"Introducing CAR-T Therapy in Kazakhstan: Establishing Academic-Scale Lentiviral Vector and CAR-T Cell Production","volume":"15","author":"V. Keyer","year":"2025","journal-title":"Biomolecules"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e397912","DOI":"10.1200\/EDBK_397912","article-title":"High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions","author":"E. R. S. Cliff","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref43","article-title":"El canciller Ebrard anuncia llegada a M\u00e9xico de nuevo tratamiento contra el c\u00e1ncer","author":"Secretar\u00eda de Relaciones Exteriores","year":"2023","journal-title":"gob.mx"},{"key":"ref44","article-title":"First two CAR-T cell medicines recommended for approval in the European Union | European Medicines Agency (EMA)","author":"European Medicines Agency (EMA)","year":"2018"},{"key":"ref45","article-title":"Fiocruz and Caring Cross announce agreement to CAR-T therapy in Brazil and Latin America","author":"Funda\u00e7\u00e3o Oswaldo Cruz (Fiocruz)","year":"2024","journal-title":"Funda\u00e7\u00e3o Oswaldo Cruz Fiocruz"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1007\/s12325-024-02917-7","article-title":"Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma","volume":"41","author":"J. Wu","year":"2024","journal-title":"Adv Ther"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e0278950","DOI":"10.1371\/journal.pone.0278950","article-title":"Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: Results from a comprehensive cancer center","volume":"17","author":"S. Chacim","year":"2022","journal-title":"PLOS ONE"},{"key":"ref48","article-title":"ABECMA (idecabtagene vicleucel)","author":"Food and drug administration (FDA)","year":"2025","journal-title":"FDA"},{"key":"ref49","article-title":"AUCATZYL","author":"Food and drug administration (FDA)","year":"2025","journal-title":"FDA"},{"key":"ref50","article-title":"BREYANZI","author":"Food and drug administration (FDA)","year":"2025","journal-title":"FDA"},{"key":"ref51","article-title":"CARVYKTI","author":"Food and drug administration (FDA)","year":"2025","journal-title":"FDA"},{"key":"ref52","article-title":"TECARTUS","author":"Food and drug administration (FDA)","year":"2025","journal-title":"FDA"},{"key":"ref53","article-title":"YESCARTA","author":"Food and drug administration (FDA)","year":"2025","journal-title":"FDA"},{"key":"ref54","article-title":"Yescarta","author":"European Medicines Agency (EMA)","year":"2018"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2217\/imt-2020-0118","article-title":"Perceptions of Community Hematologists\/Oncologists on Barriers to Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Diffuse Large B-Cell Lymphoma","volume":"12","author":"A. Gajra","year":"2020","journal-title":"Immunotherapy"},{"key":"ref56","article-title":"Tecartus","author":"European Medicines Agency (EMA)","year":"2021"},{"key":"ref57","article-title":"Kymriah","author":"European Medicines Agency (EMA)","year":"2018"},{"key":"ref58","article-title":"Carvykti","author":"European Medicines Agency (EMA)","year":"2022"},{"key":"ref59","article-title":"Breyanzi","author":"European Medicines Agency (EMA)","year":"2022"},{"key":"ref60","article-title":"Abecma","author":"European Medicines Agency (EMA)","year":"2021"},{"key":"ref61","article-title":"Aucatzyl","author":"European Medicines Agency (EMA)","year":"2025"},{"key":"ref62","article-title":"Kymriah","author":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria","year":"2025","journal-title":"Consult. ANVISA"},{"key":"ref63","article-title":"Carvykti","author":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria","year":"2025"},{"key":"ref64","article-title":"Yescarta","author":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria"},{"key":"ref65","article-title":"Anvisa aprova mais um produto de terapia avan\u00e7ada para tratamento de c\u00e2ncer no Brasil","author":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria","year":"2025"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","article-title":"Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed\/Refractory Diffuse Large B Cell Lymphoma","volume":"29","author":"M. S. Hoffmann","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jtct.2023.08.007","article-title":"Assessing Medicaid Coverage for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy: A Project from the American Society for Transplantation and Cellular Therapy and the National Marrow Donor Program ACCESS Initiative","volume":"29","author":"J. J. Auletta","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jtct.2023.07.012","article-title":"Unmet Need and Potential Barriers for Chimeric Antigen Receptor T Cell Therapy in India","volume":"29","author":"C. Singh","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1182\/blood-2024-211499","article-title":"Barriers to CAR-T Therapy Adoption: Comparing Access in Academic and Community Settings in the US","volume":"144","author":"A. Levent","year":"2024","journal-title":"Blood"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/163505-current-landscape-of-academic-and-point-of-care-car-t-cell-therapy-in-low-middle-income-countries","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:15:44Z","timestamp":1782738944000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/163505-current-landscape-of-academic-and-point-of-care-car-t-cell-therapy-in-low-middle-income-countries"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":69,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.163505","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}